Business

eXoZymes Launches Subsidiary, NCTx, to Unlock a Promising Compound for Gut and Liver Health

N-trans-caffeoyltyramine (NCT) is a natural product compound attracting considerable interest from researchers and drug developers for its potential role in healthy liver fat metabolism, gut barrier function, and mitochondrial activity. eXoZymes used ...

articleExozymes Inc.May 6, 20254/company/exozymes-inc/news/exozymes-launches-subsidiary-nctx-unlock-201000920
eXoZymes Launches Subsidiary, NCTx, to Unlock a Promising Compound for Gut and Liver Health

About this update from Exozymes Inc.

[{"type":"list","items":[{"val":[{"type":"text","content":"N-trans-caffeoyltyramine (NCT) is a natural product compound attracting considerable interest from researchers and drug developers for its potential role in healthy liver fat metabolism, gut barrier function, and mitochondrial activity.","length":236,"tagName":"p"}]},{"val":[{"type":"text","content":"eXoZymes used its AI-driven development platform to progress from idea to purpose-built subsidiary in less than 3 months and at a fraction of normal SynBio R&D cost.","length":169,"tagName":"p"}]},{"val":[{"type":"text","content":"NCTx is scaling up an exozyme biosolution to overcome a longstanding bottleneck in sourcing the NCT compound from nature, where it occurs only in trace amounts.","length":160,"tagName":"p"}]},{"val":[{"type":"text","content":"Interesting pre-clinical data point towards Non-Alcoholic Fatty Liver Disease (NAFLD) that affects more than 30% of the global population.","length":138,"tagName":"p"}]},{"val":[{"type":"text","content":"Only NCTx can make both the natural product NCT, and a range of very interesting new-to-nature analog versions, expanding the pharma potential.","length":143,"tagName":"p"}]},{"val":[{"type":"text","content":"NCT is the first of more "powered by eXoZymes" natural product nutraceuticals, that also have the potential to become pharmaceuticals.","length":144,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":990,"olType":false},{"type":"text","content":"SAN JOSE, CALIFORNIA / ACCESS Newswire / May 6, 2025 / Today at the yearly SynBioBeta conference, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - announced the formation of ‘NCTx, LLC' (NCTx), a purpose-built subsidiary company focused on the development and production of N-trans-caffeoyltyramine - a very rare, plant-derived compound with emerging relevance in the areas of metabolic health, gut integrity, and liver function.","length":577,"tagName":"p"},{"type":"text","content":"To date, NCT has not been available at commercially viable qualities and quantities. Naturally found in quantities less than 0.014% per hemp seed, its commercial use has been severely limited despite its immense potential. Using eXoZymes' AI-driven exozymes ...

More updates from Exozymes Inc.

eXoZymes Inc.NCTxsubsidiary companyACCESS Newswireforward-looking statements